Trial results
In the STEP Young trial, 167 children with obesity received either semaglutide or placebo, along with a reduced-calorie diet and increased physical activity. At week 68, the estimated mean percentage change in BMI from baseline was -17.4% with semaglutide and +2.2% with placebo, for an estimated treatment difference of -19.7 percentage points under the efficacy estimand. Under the treatment regimen estimand, the difference was -16.2 percentage points.
More than 85% of the children had class II or III severe obesity at baseline. Nearly half already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea.
At week 68, 78.7% of children treated with semaglutide had an observed reduction in BMI of 10% or more under the efficacy estimand, compared with 0% of those receiving placebo. Additionally, 40.4% of children treated with semaglutide were no longer classified as having obesity at week 68 if all children adhered to treatment, compared with 0% of those receiving placebo.